Proposal to update the existing guidance

The planned date for the consideration of a review of TA238; Tocilizumab for the treatment of systemic juvenile idiopathic arthritis, was December 2014.

This is the date when the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake an update of the existing guidance.

There is currently no new evidence that would lead to a change in the existing recommendations, however a subcutaneous formulation of tocilizumab is licensed for RA, and it is anticipated that the license for this formulation will be extended to include systemic JIA. This is likely to alter the cost-effectiveness of the tocilizumab. As a result, we propose that a review of the guidance should be planned into the Appraisals work programme to coincide with the license extension for subcutaneous tocilizumab.

NICE was unable to issue guidance on canakinumab for systemic JIA (TA302) due to a non-submission from the company, but further information may be available that would allow NICE to make recommendations for this technology.

Consequently, we believe that TA238 and TA302 should be updated in an MTA, which would consider both the intravenous and subcutaneous formulations of tocilizumab and canakinumab for the treatment of systemic juvenile arthritis.

In order to be completely confident that this is appropriate, we are asking   consultees and commentators with an interest in this topic, to inform us of any evidence which would suggest that an earlier review would be beneficial.  We would particularly like to be made aware of timelines around on-going research, etc. which might affect the scheduling of this review should we go ahead with the proposal following this consultation.

Please see appendix A for a full list of the organisations we have contacted. 

February 2015  

Attachments